Pfizer reported $14.5 billion in revenue for Q1, a 5.7% increase year-over-year and $649 million above estimates. The company’s acquired products contributed $3.1 billion with 22% operational growth, aiding its strategy to manage patent expirations. Key segments like Oncology, Specialty Care, and Hospital showed strong double-digit growth, while COVID-related Primary Care revenues declined sharply. Pfizer’s debt stands at $64.7 billion, but $7.2 billion in cost cuts could help stabilize margins and support future earnings recovery, signaling potential post-COVID business stabilization.
Pfizer remains an undervalued stock that has underperformed the market but increased 2% since the last analysis. It is viewed as a defensive holding that provides income and helps offset risks related to AI in a diversified portfolio. Despite recent ...
Pfizer is currently undervalued, trading at just over 8 times its projected 2026 earnings and offering a 7% dividend yield. Its core business, excluding COVID-related drugs, grew 7% in Q1, while new products, especially from its acquisition of Seagen...
